Extracellular vesicle comprising a fusion protein having fc binding capacity

a technology of fusion protein and extracellular vesicle, which is applied in the field of extracellular vesicle (ev) therapeutics, can solve the problems of increased surface coating of evs with the protein and fc domain, and achieve the effect of enhancing the therapeutic potential of evs

Pending Publication Date: 2022-03-31
EVOX THERAPEUTICS LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention aims to solve problems associated with the loading of EVs with protein biologics, especially antibodies, for therapeutic application. The invention provides a solution to enhance the therapeutic potential of EVs for therapeutic protein delivery. The Fc binder polypeptides of the invention can be engineered to be smaller than native Fc binders, making it easier to direct them to EV surfaces with the aid of fusion constructs with EV proteins. The Fc binder fusion proteins are efficiently displayed on the surface of EVs, enabling dense coating of EVs with Fc domain-containing proteins such as antibodies. The coating of EVs with antibodies or other Fc domain-containing proteins has several advantages, including improved targeting, enhanced therapeutic efficacy, and reduced immune-mediated clearance. The invention also provides a method to reduce opsonization and immune-mediated clearance of EVs.

Problems solved by technology

Moreover, one significant difference between non-human Fc binders (which may be e.g. bacterial in origin) and human Fc binders is the fact that such non-human Fc binders can in certain instances simultaneously bind more than one Fc domain, which may lead to increased surface coating of the EVs with the protein of interest comprising an Fc domain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extracellular vesicle comprising a fusion protein having fc binding capacity
  • Extracellular vesicle comprising a fusion protein having fc binding capacity
  • Extracellular vesicle comprising a fusion protein having fc binding capacity

Examples

Experimental program
Comparison scheme
Effect test

example 1

f IgG to EVs Comprising Fc Binding Polypeptides (Fc-Binding EVs)

[0107]EVs were isolated from the conditioned medium from engineered HEK293T cells (control versus Fc-binding construct that stably express Gp130 Extracellular domain-2XGGGGS linker-Z domain-Gp130 transmembrane domain-Leucine Zipper-N terminal syntenin-His tag) using tangential flow filtration with 300 kd hollow fiber columns, followed by ultrafiltration using 10 kd spin filters for concentration. The binding capacity for IgG by the Fc-binding EVs were then assessed using electron microscopy and flow cytometry.

[0108]For electron microscopy, 1×10{circumflex over ( )}9 EVs were incubated with Rabbit anti-goat 10 nm antibody conjugated with gold Nanoparticles for 2 h at 37° C. As shown in FIG. 2, Fc-binding EVs (A) are decorated with nanogold labeled antibodies (i.e. Fc containing proteins), whereas control EVs (B) do not have any antibodies bound.

[0109]For flow cytometry, 1×10{circumflex over ( )}8 EVs were incubated overn...

example 2

mp2B EVs for Delivery of Anti-HER2 Antibody

[0110]EVs were isolated from HEK293T cells (either stably expressing FCGR1A Extracellular domain-4XGSlinker-Lamp2b or their wild type controls) using ultrafiltration and size exclusion chromatography. EVs were labelled with PKH26 red fluorescent dye, and decorated with anti-HER2 antibody or its isotype control by co-incubating EVs and antibody for 1 h at 37° C. Unbound antibody was removed by size exclusion chromatography. Uptake of antibody decorated EVs was characterized in HER2 low-expressing cell line MDA-MB-231 and in HER2 high-expressing cell line MDA-MB-361 using flow cytometry. FIG. 4 shows that anti-HER2 antibody increases uptake of decorated EVs as compared to isotype control decorated and wild type EVs only in HER2 high-expressing cell line MDA-MB-361, but not in HER2 low-expressing cell line MDA-MB-231. Similar results were obtained with EVs expressing CD63-ZZ fusion proteins.

example 3

t Delivery by EVs Comprising CD81-Protein A / G Fusion Proteins

[0111]EVs were isolated from HEK293T cells (either stably expressing CD81-ProteinA / G CD81 Second loop fusion protein or their wild type control) using ultrafiltration and size exclusion chromatography. EVs were decorated with etanercept or a control antibody by co-incubating EVs and etanercept for 1 h at 37° C. Unbound etanercept was removed by size exclusion chromatography. To study anti-inflammatory effect of the etanercept-decorated EVs, the well-studied TNBS-induced colitis mouse model was used. This model simulates the gut inflammation, cytokine storm and weight decrease associated with IBD patients. 24 mice were divided into four treatment groups, with 6 mice per group. The mice were pre-sensitized by applying 150 μl of a olive oil-acetate solution with 2% TNBS, on the skin, 1 week prior to colitis induction. Colitis was then induced by giving a rectal infusion of 100 μl solution containing 1.5% TNBS in 40% ethanol. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs are coated with proteins containing Fc domains (such as antibodies) for i.a. targeting and therapeutic applications. The coating of EVs is achieved through inventive protein engineering of EV polypeptides. The present invention thus relates to methods for coating of EVs, EVs per se, as well as pharmaceutical compositions and medical applications of such EVs coated with Fc containing proteins.

Description

RELATED APPLICATIONS[0001]This application is a division of U.S. application Ser. No. 16 / 319,061, filed on Jan. 18, 2019, which is a U.S. National Phase Application, filed under U.S.C. § 371, of International PCT Application No. PCT / EP2017 / 068476, filed Jul. 21, 2017, which claims the priority benefit of GB 1612643.5, filed Jul. 21, 2016, the contents of each of which are herein incorporated by reference in their entirety.INCORPORATE-BY-REFERENCE OF SEQUENCE LISTING[0002]The contents of the file named “EVOX-006_D01US_SeqListing_ST25”, which was created on Dec. 15, 2021, and is 313 KB in size are hereby incorporated by reference in their entirety.TECHNICAL FIELD[0003]The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs are coated with proteins comprising Fc domains (such as antibodies) for i.a. targeting and therapeutic applications.BACKGROUND ART[0004]Protein biologics are routinely used in the treatment and / or prevention of a wide range of dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/705A61K47/69A61K47/64A61K9/127A61K47/24C07K14/47
CPCC07K14/705A61K47/6913A61K47/64A61K38/00A61K47/24C07K14/47A61K9/1271A61K39/44C07K2319/30A61P29/00A61P35/00A61P37/06A61P43/00C07K14/31C07K14/315C07K2319/33C07K2319/03A61K47/6901A61K47/46C07K14/195C07K2319/705C07K16/32G01N33/532G01N33/554
Inventor WIKLANDER, OSCARGÖRGENS, ANDRÉGUPTA, DHANU
Owner EVOX THERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap